Free Trial
TSE:MDNA

Medicenna Therapeutics (MDNA) Stock Price, News & Analysis

Medicenna Therapeutics logo
C$1.26 -0.01 (-0.79%)
As of 03:59 PM Eastern

About Medicenna Therapeutics Stock (TSE:MDNA)

Key Stats

Today's Range
C$1.23
C$1.30
50-Day Range
C$1.26
C$1.99
52-Week Range
C$0.43
C$2.98
Volume
11,622 shs
Average Volume
63,026 shs
Market Capitalization
C$96.30 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

Receive MDNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medicenna Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

MDNA Stock News Headlines

Medicenna’s MDNA11 Shows Promising Cancer Treatment Results
Bill O’Reilly: “the best-prepared president in history.”
"We're going to bring back the American Dream... bigger, better, bolder, richer, safer, and stronger than ever before." - President Donald Trump During Trump's first term, 8 million Americans became millionaires despite constant resistance from Democrats and even some Republicans in his cabinet. Now, with Republicans controlling both houses and the Fed cutting rates, everything is aligned for even greater growth.
Medicenna Reports Promising Results with MDNA11
See More Headlines

MDNA Stock Analysis - Frequently Asked Questions

Medicenna Therapeutics' stock was trading at C$1.65 at the beginning of 2025. Since then, MDNA shares have decreased by 23.6% and is now trading at C$1.26.
View the best growth stocks for 2025 here
.

Shares of MDNA stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.

Based on aggregate information from My MarketBeat watchlists, some other companies that Medicenna Therapeutics investors own include Manulife Financial (MFC), Gilead Sciences (GILD), OPKO Health (OPK), Air Canada (AC), Athersys (ATHX), Birchcliff Energy (BIR) and Canadian Natural Resources (CNQ).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Pharmaceutical Products
CIK
N/A
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Net Income
C$-26,240,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Cash Flow
C$1.13 per share
Book Value
C$0.30 per share

Miscellaneous

Free Float
N/A
Market Cap
C$99.36 million
Optionable
Not Optionable
Beta
1.21
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.

Get This Free Report

This page (TSE:MDNA) was last updated on 2/4/2025 by MarketBeat.com Staff
From Our Partners